Stock Region Penny Picks
Good Morning, Stock Region!
Good Morning, Stock Region!
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The information in this newsletter is for informational and entertainment purposes only. It is not financial advice. All investing involves risk, and you should conduct your own research or consult with a qualified financial professional before making any investment decisions. The authors may hold positions in the stocks mentioned.
What a day in the markets. We saw some wild moves, some gut-wrenching drops, and a few diamonds in the rough that really caught my eye. The biotech sector was on fire, for better or for worse, and a few other names popped up with news that’s too good to ignore. Let’s break down what’s on my radar for today.
The Watchlist: Movers & Shakers
$SKYE - Skye Bioscience
Kicking things off with some intriguing biotech news. Skye Bioscience is presenting data at ObesityWeek 2025. They’re talking about improving “rebound weight gain.” This is a massive issue with current weight-loss drugs. If SKYE has a legitimate solution, this could be a game-changer. The weight-loss market is colossal, and any company that can solve a major side effect is worth watching. I’m keeping a close eye on this one for a potential catalyst.
$JYD - Jayud Global Logistics
Here’s a name that might fly under the radar. Jayud just got selected by Lenovo for warehousing and logistics. Landing a contract with a giant like Lenovo is a huge vote of confidence. This isn’t just a small win; it’s a major validation of their services. I’m looking for this to provide a nice, steady tailwind for JYD. It’s the kind of fundamental news that can build long-term value.
$CHR - Cheer Holding
Things are getting interesting for Cheer Holding. The company announced it received two non-binding proposals to be acquired. A bidding war could be on the horizon. When buyers start circling, it often means they see deep, untapped value. This situation could get spicy. I’ll be watching for any further news on these proposals. An acquisition could lead to a significant premium for shareholders.
$NXPL - NextPlat Corp
Solid contract win here. NXPL’s subsidiary, PharmcoRx, landed a multi-state prescription fulfillment deal with DevotedDoc. This is bread-and-butter business that adds to the bottom line. It shows the company is executing and expanding its footprint. These types of contracts are what build a stable revenue base. Definitely a positive development.
$PRFX - PainReform
PainReform is making moves in the tech space through its DeepSolar unit, which is part of the NVIDIA Connect Program. Being associated with a name like NVIDIA is a massive credibility boost. They’re developing a predictive AI tool and talking about pilot projects. The “AI” halo effect is real, and linking up with NVIDIA puts them in the spotlight. This could attract a lot of new investor attention.
$LNAI - Lunai Bioworks
This is the kind of news that makes you do a double-take. LNAI announced a complete regression of pancreatic tumors in preclinical models. Let that sink in. Pancreatic cancer is notoriously difficult to treat. While it’s still early (preclinical), this is a monumental breakthrough. This news is explosive. I expect a lot of volatility and excitement around LNAI. This is a high-risk, high-reward play, but the potential is undeniable.
$BHVN - Biohaven
And now for the other side of the biotech coin. Biohaven received a Complete Response Letter (CRL) from the FDA for its spinocerebellar ataxia drug. A CRL is essentially a rejection, and it’s a major setback. The stock will likely take a beating on this news. It’s a harsh reminder of the brutal reality of drug development. I’d be steering clear until there’s a clear path forward for the company.
$IRWD - Ironwood Pharmaceuticals
Here’s some good news from the FDA. IRWD got approval for a drug treating IBS with constipation in children. Opening up a drug to a new, younger patient population is a significant market expansion. This approval provides a new revenue stream and strengthens the drug’s market position. It’s a solid win for the company.
$FSLY - Fastly
Ending on a high note! Fastly posted a fantastic Q3. Record revenue that beat their own guidance, record cash from operations, and positive free cash flow. This is what you want to see from a growth company—execution. After a period of skepticism from the market, seeing these kinds of numbers is incredibly encouraging. It suggests the turnaround is not just real, but accelerating. I’m definitely bullish on this report.
Final Disclaimer: Remember, the market is unpredictable. This watchlist is a starting point for your own research. Never invest more than you are willing to lose. Trade smart, stay informed, and good luck out there.